Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Felix Orben

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2196-8702; OpenAlex author ID A5043644513. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
73
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 4 papers · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 11

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  3. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  4. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  5. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. First author DOI 10.1055/a-2257-3171↗
  6. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  7. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2105691119↗
  8. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  9. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  10. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  11. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Reichert · 11 shared papers, 2020–2026 · strength 1.51
  2. Günter Schneider · 10 shared papers, 2020–2026 · strength 1.30
  3. Roland Michael Schmid · 7 shared papers, 2020–2026 · strength 1.04
  4. Roland Rad · 8 shared papers, 2020–2026 · strength 1.00
  5. Dieter Saur · 8 shared papers, 2020–2026 · strength 1.00
  6. Matthias Wirth · 7 shared papers, 2020–2026 · strength 0.84
  7. Christian Schneeweis · 5 shared papers, 2020–2026 · strength 0.65
  8. Lukas Krauß · 4 shared papers, 2022–2026 · strength 0.57
  9. Carolin Schneider · 4 shared papers, 2022–2026 · strength 0.57
  10. H. Carlo Maurer · 3 shared papers, 2022–2025 · strength 0.49
  11. İhsan Ekin Demir · 3 shared papers, 2022–2025 · strength 0.49
  12. Christoph Schlag · 4 shared papers, 2020–2024 · strength 0.47
  13. Wilko Weichert · 4 shared papers, 2020–2025 · strength 0.47
  14. Oliver Holger Krämer · 3 shared papers, 2022–2026 · strength 0.44
  15. Bernhard Küster · 3 shared papers, 2022–2025 · strength 0.42
  16. Ulrich Bernd Keller · 3 shared papers, 2020–2026 · strength 0.39
  17. Aristeidis Papargyriou · 3 shared papers, 2020–2025 · strength 0.38
  18. Michael B. Ghadimi · 2 shared papers, 2024–2026 · strength 0.33
  19. Marian Grade · 2 shared papers, 2024–2026 · strength 0.33
  20. Constanza Tapia Contreras · 2 shared papers, 2024–2026 · strength 0.33
  21. Elisabeth Heßmann · 2 shared papers, 2024–2026 · strength 0.33
  22. Volker Ellenrieder · 2 shared papers, 2024–2026 · strength 0.33
  23. Zonera Hassan · 3 shared papers, 2020–2022 · strength 0.32
  24. Hazal Köse · 2 shared papers, 2022–2026 · strength 0.31
  25. Janine Murr · 2 shared papers, 2022–2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.